230
Views
45
CrossRef citations to date
0
Altmetric
Research Article

Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery

&
Pages 779-786 | Received 20 May 2010, Accepted 20 Sep 2010, Published online: 14 Sep 2011
 

Abstract

Context: Skin delivery of Meloxicam (MX) offers several advantages over the oral route which is associated with potential side effects.

Objectives: The aim of this study was to develop transdermal MX in niosomes.Materials and Methods: Vesicles prepared by thin film hydration method were characterized and the acute anti-inflammatory activity of 0.5% MX niosomal hydrogel was evaluated using carrageenan induced rat paw edema method. Results: The results revealed that niosomes prepared from span 60 and cholesterol at 6:4 molar ratio using 20 mg of MX were of the highest entrapment efficiency (> 55%) and with particle size (187.3 nm). There was a marked increase in the percentage inhibition of edema in animals treated with MX vesicular gel compared to those treated with free MX and piroxicam gels.

Discussion: There was an inverse proportionality between vesicle size and cholesterol content. With increased cholesterol molar ratio the bilayer stability increased and permeability decreased leading to efficiently trapping the MX. In contrast, higher amounts of cholesterol may compete with the drug for packing space within the bilayer. The inhibitory effect of MX niosomal gel may be attributed to its superior skin permeation.

Conclusions: The results suggest that niosomes may be promising vehicles for transdermal delivery of MX.

Acknowledgments

The authors are very grateful to Dr. Amera Morad (Department of Pharmacology, Beni Suef University) for her support in the in vivo experiment.

Declaration of interest

The authors have no conflict of interest to report.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.